Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Validea
$12.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mallinckrodt Plc New Drug Application approved by FDA


Friday, 17 Jan 2014 07:00am EST 

Mallinckrodt Plc:Says the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for PENNSAID (diclofenac sodium topical solution) two pct w/w.PENNSAID two pct is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knee(s). 

Latest Developments for Mallinckrodt Inc

Related Company News